Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix’s PSMA-PET molecular imaging technologies and Profound’s MRI-guided TULSA-PRO® ...
Good evening and welcome to Doctors on Call back on our we're back on our 45th season at this time. I'm Dr. Ray Christensen, ...
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announced that it will host a Capital Markets Day in Melbourne, Australia, on Wednesday, November 4, 2026, from 9:00 a.m. to 12:30 ...
Fear of accusations of infidelity, the stigma surrounding HIV and concerns about causing conflict in a relationship might ...
For men diagnosed with localized prostate cancer, radiation treatment has long meant a difficult trade-off: either endure ...
DSS Takara Bio supports prostate cancer research through molecular profiling, transcriptomics and sequencing technologies for ...
Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver ...
FDA Fast Track designation granted for Telix's BiPASS® program, which is evaluating 68Ga-PSMA-PET imaging alongside MRI in the pre-biopsy prostate cancer setting. The designation recognizes the ...
Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging. Melbourne (Australia) and Indianapolis, IN (United States) \| September 30, 2026. FDA Fast T ...
Medicus Pharma submitted a seamless Phase 2b/3 protocol to the FDA for Teverelix, targeting advanced prostate cancer with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results